Q-omics provides the consensus-scored SNAP25 profile across patient tissues and cancer cell-line models. SNAP25 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SNAP25 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SNAP25 protein abundance shows 19,250 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where SNAP25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNAP25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNAP25 survival associations across molecular data types. SNAP25 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNAP25 RNA expression–survival associations across cancer types. High SNAP25 expression shows unfavorable associations in LUSC, UCEC and LIHC, but favorable associations in HNSC, LUAD and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SNAP25 RNA expression.
This table summarizes SNAP25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SNAP25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNAP25 shows lower tumor expression in COAD and UCEC and higher tumor expression in KIRC, THCA, HNSC and KIRP. The KIRC box plot shows higher SNAP25 RNA expression in tumor versus normal tissue (log2 FC = +1.717, t-test p < 0.001).
This table shows molecular features associated with SNAP25 in patient tissues and cancer cell lines. In patient samples, SNAP25 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SNAP25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_SCLC.
